. Author manuscript; available in PMC: 2012 Jan 1.

Published in final edited form as: Adv Chronic Kidney Dis. 2011 Jan;18(1):28–41. doi: 10.1053/j.ackd.2010.10.003

TABLE 4.

Characteristics and Achieved Blood Pressures in Diabetic Nephropathy Studies Using Mineralocorticoid Receptor Antagonists

	Population/Proteinuria	Treatment	Achieved BP (mmHg)
Schjoedt 2005 (87)	DM1; 300mg/d (already on ACEi or ARB)	Spironolactone Placebo	136/69 144/72 24 hr SBP p=.082, 24 hr DBP p=.067
Schjoedt 2006 (88)	DM1 or 2; 2.5g/d (already on ACEi or ARB)	Spironolactone Placebo	137/77 143/81 24 hr SBP p=.004, 24 hr DBP p=.001
Mehdi 2009 (89)	DM1 or 2; 300 mg/g Cr	Spironolactone Losartan Placebo (already on Lisinopril 80 mg)	132 134 136 (NS between groups)

DM 1 (or 2): Diabetes Mellitus Type 1 or 2; SBP=Systolic Blood Pressure; DBP=Diastolic Blood Pressure; ACEi=Angiotensin Converting Enzyme Inhibitor; ARB=Angiotensin Receptor Blocker